{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:29:18Z","timestamp":1771644558378,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejca.2017.05.016","type":"journal-article","created":{"date-parts":[[2017,7,23]],"date-time":"2017-07-23T02:46:14Z","timestamp":1500777974000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study"],"prefix":"10.1016","volume":"83","author":[{"given":"Christophe","family":"Massard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Farace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Clement","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Dieras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Ferte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2017.05.016_bib1","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/onc.2015.192","article-title":"The biology of circulating tumor cells","volume":"35","author":"Pantel","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.016_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrclinonc.2013.253","article-title":"Molecular analysis of circulating tumour cells-biology and biomarkers","volume":"11","author":"Krebs","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.05.016_bib3","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1158\/1078-0432.CCR-13-2664","article-title":"Circulating tumor cells: a multifunctional biomarker","volume":"20","author":"Yap","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.016_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.016_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201303698","article-title":"Biology, detection, and clinical implications of circulating tumor cells","volume":"7","author":"Joosse","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejca.2017.05.016_bib6","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.05.016_bib7","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.05.016_bib9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","article-title":"Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib10","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2017.05.016_bib11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.016_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdu513","article-title":"Phase I trials in oncology: a new era has started","volume":"26","author":"Postel-Vinay","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.05.016_bib13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/1078-0432.CCR-09-1993","article-title":"An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.016_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CCO.0b013e32835ff3cb","article-title":"Biomarker-driven patient selection for early clinical trials","volume":"25","author":"Dienstmann","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.05.016_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1-standardisation and disease-specific adaptations: perspectives from the RECIST Working Group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.05.016_bib17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib18","first-page":"iii24","article-title":"Kinetics of tumor growth in patients included in Phase I trials. TAT processings","author":"Gomez-Roca","year":"2008","journal-title":"Ann Onc"},{"key":"10.1016\/j.ejca.2017.05.016_bib19","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","article-title":"Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST","volume":"22","author":"Ratain","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-319-22909-6_10","article-title":"Circulating tumor cells","volume":"882","author":"Paoletti","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"15","key":"10.1016\/j.ejca.2017.05.016_bib21","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-10-3019","article-title":"Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials","volume":"17","author":"Olmos","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.016_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1078-0432.CCR-15-1008","article-title":"Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms","volume":"22","author":"Khan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ejca.2017.05.016_bib23","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-13-2819","article-title":"Circulating tumor cells in patients with testicular germ cell tumors","volume":"20","author":"Nasta\u0142y","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.016_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/annonc\/mdu207","article-title":"Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance","volume":"26","author":"Khoja","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","article-title":"Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system","volume":"13","author":"Riethdorf","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.05.016_bib26","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1158\/1078-0432.CCR-05-1769","article-title":"Circulating tumor cells versus imaging\u2013predicting overall survival in metastatic breast cancer","volume":"12","author":"Budd","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.05.016_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2016.04.024","article-title":"Liquid biopsy-based clinical research in early breast cancer: the EORTC 90091-10093 Treat CTC trial","volume":"63","author":"Ignatis","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.05.016_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2017.05.016_bib29","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-12-1587","article-title":"Meta-analysis of the prognostic value of circulating tumor cells in breast cancer","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.ejca.2017.05.016_bib30","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.05.016_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.molonc.2016.01.001","article-title":"Circulating tumor cells in breast cancer","volume":"10","author":"Bidard","year":"2016","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.05.016_bib32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/annonc\/mdp463","article-title":"Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents","volume":"21","author":"Tol","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.05.016_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdn544","article-title":"Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience","volume":"20","author":"Olmos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2017.05.016_bib35","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.05.016_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.gde.2013.11.013","article-title":"Genomes in the clinic: the Gustave Roussy Cancer Center experience","volume":"24","author":"Lacroix","year":"2014","journal-title":"Curr Opin Genet Dev"},{"issue":"13","key":"10.1016\/j.ejca.2017.05.016_bib37","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2017.05.016_bib38","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-15-0584","article-title":"Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration","volume":"21","author":"Frenel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2017.05.016_bib39","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1158\/1078-0432.CCR-15-2470","article-title":"Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial","volume":"22","author":"Jovelet","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2017.05.016_bib40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.2010.34.5074","article-title":"Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors","volume":"30","author":"Olmos","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917309711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917309711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T12:11:53Z","timestamp":1569931913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917309711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":40,"alternative-id":["S0959804917309711"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}